Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for amivantamab-vmjw to identify patients with inoperable or recurrent NSCLC harbouring EGFR exon 20 insertion mutations, Business News

What the Approval Means for Lung Cancer Diagnostics

Lung cancer remains one of the most prevalent and deadly cancers worldwide, with non-small cell lung cancer accounting for approximately 80-85% of all lung cancer cases. In Japan alone, more than 136,000 new lung cancer cases were diagnosed in 2022, underscoring the substantial patient population that could benefit from advanced diagnostic tools.

EGFR exon 20 insertion mutations represent a challenging molecular subtype of NSCLC. Retrospective analyses have shown that the Guardant360 test identifies these mutations in approximately 2.4% of East Asian NSCLC patients, including those from Japan, highlighting the relevance of this approval for the local population. For patients whose tumours are inoperable or have returned after treatment, accessing targeted therapy depends on accurate and timely identification of these mutations.

Traditional tissue biopsies can be difficult due to tumour location, patient frailty, or insufficient sample quality. Liquid biopsy technology offers a minimally invasive alternative by analysing circulating tumour DNA (ctDNA) shed into the bloodstream, providing comprehensive genomic profiling from a simple blood draw. This allows oncologists to obtain clinically relevant information more quickly and match patients to the most appropriate personalised treatment.

Guardant360 CDx: Expanding Companion Diagnostic Indications

Guardant360® CDx is a comprehensive genomic profiling panel that examines 74 cancer-related genes using next-generation sequencing. The test had previously received MHLW approval in March 2022 for comprehensive genomic profiling in patients with advanced solid tumours.

Prior to this latest expansion, the test was already authorised as a companion diagnostic for several cancer drugs in Japan. These include treatments targeting KRAS G12C mutations (sotorasib), ERBB2 (HER2) mutations (trastuzumab deruxtecan), BRAF V600E mutations in colorectal cancer (encorafenib, binimetinib and cetuximab), KRAS/NRAS wild-type status (cetuximab or panitumumab), ERBB2 copy number alterations (trastuzumab and pertuzumab), MSI-High tumours (nivolumab), and solid tumours (pembrolizumab). The addition of EGFR exon 20 insertion mutation detection for amivantamab-vmjw further broadens its clinical utility.

For patients in Japan with inoperable or recurrent NSCLC harbouring EGFR exon 20 insertion mutations, the new approval creates a greater opportunity to access targeted treatment options such as amivantamab-vmjw combined with chemotherapy. Janssen Pharmaceutical K.K., a Johnson & Johnson company, is currently seeking regulatory approval for amivantamab-vmjw in Japan, and this companion diagnostic approval helps prepare the groundwork for potential future availability of the therapy.

Business and Commercial Implications

This regulatory achievement demonstrates Guardant Health's continued expansion in the Asian market and reinforces its position as a leader in precision oncology. Founded in 2012, the company focuses on transforming patient care through advanced blood and tissue tests, real-world data, and AI analytics. Its mission centres on guarding wellness and giving people more time free from cancer by providing critical insights into disease drivers across all stages of care.

From a commercial perspective, the integration of liquid biopsy testing into standard clinical practice represents a shift towards more patient-friendly diagnostic approaches while maintaining the scientific rigour necessary for effective treatment selection. For business consumers, investors, and procurement stakeholders in healthcare and life sciences, the development signals ongoing innovation in the companion diagnostics sector and the growing commercial potential of tests that enable targeted therapies.

The approval process involved rigorous evaluation by Japanese regulatory authorities, reflecting the high standards required for companion diagnostics that directly influence treatment decisions. As with any medical innovation, the implementation of liquid biopsy testing requires appropriate training for healthcare professionals, integration into clinical workflows, and consideration of reimbursement pathways to ensure broad patient access.

Broader Trends in Precision Oncology

The success of Guardant360® CDx in Japan may pave the way for similar approvals in other Asian markets and contribute to the growing global adoption of liquid biopsy technologies. As healthcare systems increasingly prioritise personalised medicine approaches, minimally invasive diagnostic tools that deliver timely, actionable genomic information are likely to play an increasingly important role in oncology care.

Healthcare providers in Japan now have access to a validated blood-based tool that can help identify patients who may benefit from EGFR exon 20-targeted therapies, potentially reducing the need for repeat invasive procedures and accelerating time-to-treatment decisions. This advancement aligns with broader trends in healthcare that value patient comfort, diagnostic accuracy, and therapeutic precision.

As the oncology landscape continues to evolve with new targeted therapies entering the market, companion diagnostics like Guardant360® CDx will remain essential for matching the right patients with the right treatments at the right time. The approval in Japan represents not only a regulatory milestone for Guardant Health but also a step forward in making advanced cancer care more accessible and patient-centric.

What this means

Guardant Health Japan's MHLW approval for Guardant360® CDx as a companion diagnostic for EGFR exon 20 insertion mutations is a meaningful step forward for both patients and the precision oncology market in Japan. By offering the first blood-based test of its kind for this mutation, the company is helping to reduce diagnostic barriers and create clearer pathways to targeted therapy. For healthcare providers, investors, and business consumers tracking innovation in diagnostics and personalised medicine, the development underscores how liquid biopsy technologies are reshaping cancer care and opening new commercial opportunities across Asian and global markets.